soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm New Science Suggests Semaglutide Improves CV Outcomes Beyond Weight Loss Cardiovascular risk reduction with once-weekly

Compounding pharmacies are creating effective, legitimate medications, but those medications need more careful handling than their brand-name counterparts

The rampant off-label use of semaglutide, Ross said, suggests patients are not seeing obesity or diabetes clinicians, which means their health care providers may be even less familiar with any contraindications or side effects

2020, DOI:10.1172/jci.insight.133429 4

The risk of hypoglycemia is increased when it is used in combination with insulin secretagogues (sulfonylureas) or insulin

Make sure you can see it well and it matches what you need

Physical and metabolic changes beyond weight loss may also occur